Clinical pharmacology of moxalactam in patients with malignant disease.
Pharmacological studies of moxalactam were conducted with 37 cancer patients. Intramuscular administration of 500 mg of moxalactam to 10 patients produced a mean peak serum concentration of 12.4 micrograms/ml. The serum terminal-phase half-life was 3.9 h. Intravenous administration of 500 mg of moxa...
Spremljeno u:
| Izdano u: | Antimicrob Agents Chemother |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society for Microbiology (ASM)
1981
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC181493/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6454389/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.19.4.639 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|